Paradigm Biopharmaceuticals Ltd. (ASX: PAR) Reports Completion of Phase 3 Enrolment and Announces Options Listing
Paradigm Biopharmaceuticals Ltd. (ASX: PAR) announced on 15 June 2026 that enrolment in its pivotal Phase 3 clinical trial, PARA_OA_012, evaluating the injectable pentosan polysulfate sodium (iPPS, Zilosul®), has been completed on schedule. The company noted that this milestone removes a significant execution risk and positions the trial for an interim analysis in September 2026 and top‑line results in Q1 CY2027. An investor webinar is scheduled for 18 June 2026 at 11:00 AEST to discuss the trial and upcoming corporate milestones.
Phase 3 Trial Milestones
| Item | Detail |
|---|---|
| Trial name | PARA_OA_012 |
| Therapeutic area | Knee osteoarthritis pain |
| Study drug | Injectable pentosan polysulfate sodium (iPPS, Zilosul®) |
| Enrolment status | Completed on schedule |
| Interim analysis | Planned September 2026 |
| Top‑line results | Planned Q1 CY2027 |
The completion of enrolment is described as a “significant execution milestone” that de‑risks the Phase 3 program and introduces a period of multiple clinical and corporate catalysts for Paradigm.
Options Listing
On 17 June 2026, Paradigm announced the application for quotation of listed options on its shares. The options are set to expire on 1 December 2026 with an exercise price of $0.2375 per share. The total number of options to be quoted is 117,069,101, with the issue date of 15 June 2026. The announcement refers readers to the full Options Prospectus for detailed terms and conditions.
Shareholder Structure (as of 15 June 2026)
The top twenty holders of the listed options were disclosed, with HSBC Custody Nominees (Australia) Limited holding the largest block at 9.25 % of the options, followed by Citicorp Nominees Pty Limited (8.93 %) and Morgan Stanley Australia Securities (Nominee) Pty Limited (8.05 %). Other significant holders include Mr. Anthony Mark Van Der Steeg (4.50 %) and HSBC Custody Nominees (Australia) Limited – GSCO ECA (3.51 %).
Financial Context
- Market Capitalisation: 84,070,000 AUD (as of 14 June 2026)
- Closing price (14 June 2026): 0.155 AUD
- 52‑week high (3 July 2025): 0.48 AUD
- 52‑week low (9 June 2026): 0.135 AUD
- Price‑Earnings ratio: –1.53 (negative due to ongoing R&D costs)
Paradigm Biopharmaceuticals Ltd. remains headquartered in Melbourne, Australia, and focuses on developing pharmaceutical‑grade polysaccharide drugs for respiratory diseases, including allergic asthma, allergic rhinitis, and chronic obstructive pulmonary disease. The company’s website, www.paradigmbiopharma.com , provides further information on its pipeline and corporate updates.
